Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Hansson

Showing results (41-50 of 84) with videos related to

Pageof 9
Sort By:
Scientific Reports|December 20, 2023
Higher cyclosporine-A concentration increases the risk of relapse in AML following allogeneic stem cell transplantation from unrelated donors using anti-thymocyte globulinMikael Lisak, Malin Nicklasson, Robert Palmason, et al.
European Journal of Cancer (Oxford, England : 1990)|February 20, 2024
Real-world treatment patterns and outcomes for patients with multiple myeloma in Denmark, Finland and Sweden: An analysis using linked Nordic registriesNiels Abildgaard, Pekka Anttila, Anders Waage, et al.
Clinical Epidemiology|September 25, 2023
Use of Linked Nordic Registries for Population Studies in Hematologic Cancers: The Case of Multiple MyelomaNiels Abildgaard, Jonatan Freilich, Pekka Anttila, et al.
European Journal of Cancer (Oxford, England : 1990)|November 25, 2018
All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myelomaMeletios A Dimopoulos, Sebastian Grosicki, Wiesław W Jędrzejczak, et al.
European Journal of Haematology|November 17, 2019
Outcome and characteristics of non-measurable myeloma: A cohort study with population-based data from the Swedish Myeloma RegistryGöran Wålinder, Jan Samuelsson, Per Näsman, et al.
European Journal of Haematology|May 26, 2017
Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Population-based data from the Swedish Myeloma RegisterHareth Nahi, Anna Genell, Göran Wålinder, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 30, 2022
Cobimetinib Alone and Plus Venetoclax With/Without Atezolizumab in Patients With Relapsed/Refractory Multiple MyelomaFredrik Schjesvold, Bruno Paiva, Vincent Ribrag, et al.
Cancer Reports (Hoboken, N.J.)|March 4, 2022
Regional differences in treatment and outcome for myeloma patients in Sweden: A population based Swedish myeloma register studyGöran Wålinder, Anna Genell, Gunnar Juliusson, et al.
Blood Advances|May 21, 2020
Search for multiple myeloma risk factors using Mendelian randomizationMolly Went, Alex J Cornish, Philip J Law, et al.
Cancer Cell|April 20, 2013
A human ICAM-1 antibody isolated by a function-first approach has potent macrophage-dependent antimyeloma activity in vivoNiina Veitonmäki, Markus Hansson, Fenghuang Zhan, et al.
Pageof 9

Showing results (41-50 of 84) with videos related to

Sort By:
Pageof 9
Scientific Reports|December 20, 2023
Higher cyclosporine-A concentration increases the risk of relapse in AML following allogeneic stem cell transplantation from unrelated donors using anti-thymocyte globulinMikael Lisak, Malin Nicklasson, Robert Palmason, et al.
European Journal of Cancer (Oxford, England : 1990)|February 20, 2024
Real-world treatment patterns and outcomes for patients with multiple myeloma in Denmark, Finland and Sweden: An analysis using linked Nordic registriesNiels Abildgaard, Pekka Anttila, Anders Waage, et al.
Clinical Epidemiology|September 25, 2023
Use of Linked Nordic Registries for Population Studies in Hematologic Cancers: The Case of Multiple MyelomaNiels Abildgaard, Jonatan Freilich, Pekka Anttila, et al.
European Journal of Cancer (Oxford, England : 1990)|November 25, 2018
All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myelomaMeletios A Dimopoulos, Sebastian Grosicki, Wiesław W Jędrzejczak, et al.
European Journal of Haematology|November 17, 2019
Outcome and characteristics of non-measurable myeloma: A cohort study with population-based data from the Swedish Myeloma RegistryGöran Wålinder, Jan Samuelsson, Per Näsman, et al.
European Journal of Haematology|May 26, 2017
Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Population-based data from the Swedish Myeloma RegisterHareth Nahi, Anna Genell, Göran Wålinder, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 30, 2022
Cobimetinib Alone and Plus Venetoclax With/Without Atezolizumab in Patients With Relapsed/Refractory Multiple MyelomaFredrik Schjesvold, Bruno Paiva, Vincent Ribrag, et al.
Cancer Reports (Hoboken, N.J.)|March 4, 2022
Regional differences in treatment and outcome for myeloma patients in Sweden: A population based Swedish myeloma register studyGöran Wålinder, Anna Genell, Gunnar Juliusson, et al.
Blood Advances|May 21, 2020
Search for multiple myeloma risk factors using Mendelian randomizationMolly Went, Alex J Cornish, Philip J Law, et al.
Cancer Cell|April 20, 2013
A human ICAM-1 antibody isolated by a function-first approach has potent macrophage-dependent antimyeloma activity in vivoNiina Veitonmäki, Markus Hansson, Fenghuang Zhan, et al.
Pageof 9